Several studies have found an association of MYBL2 with malignant tumour development, such as breast, bladder, lung adenocarcinoma, and ovarian cancer (Liu Q et al., 2022; Inoue and Fry, 2016; Lee et al., 2022; Liu W et al., 2022). This evidence concerns the gene MYBL2 and ovarian carcinoma.